中国医学创新Issue(17)：3-4,2.DOI:10.3969/j.issn.1674-4985.2013.17.002
重组人p53腺病毒联合化疗治疗颈部转移癌的临床疗效观察
The Clinical Observation of Recombinant Adenovirus p53 Injection Combined with Chemotherapy in the Treatment of Neck Metastatic Carcinoma
常娜 1吴韦炜 1徐成胜 1钱立庭1
作者信息
- 1. 安徽省肿瘤医院 安徽 合肥 230031
- 折叠
摘要
Abstract
Objective:To evaluate the efficacy and toxicity of recombinant adenovirus p53 injection(rAd-p53 or gendicine)combined with chemotherapy in the treatment of neck metastatic carcinoma.Method:26 patients which had been treated by gendicine in our department from July 2009 to March 2012 were selected,they were confirmed to be the neck metastatic carcinoma by the histologically or cytologically. The changing of the tumor size was measured by type-B ultrasound before and after each treatment,then the curative effect was judged with response evaluation criteria in solid tumors(RECIST). The quality of patients’life was evaluated by Karnofsky performance score(KPS). Result:All the 26 patients had received efficacy evaluation after four weeks’treatment ,there were 9 cases of complete remission(CR),12 cases achieved partial remission(PR),2 cases of stable disease(SD),3 cases of progressive disease(PD),that is,the total effective rate(CR+PR)was 80.8%(21/26)and disease control rate(CR+PR+SD) was 88.5%(23/26). The quality of life was improved on 21 cases,stabled on 2 cases,and decreased on 3 cases. The fever was the common adverse reaction of gendicine,mostly it was self limited low fever(37.3-38.3℃),so the patients were able to tolerate. Conclusion:It is demonstrated that the use of gendicine combined with“DF”chemotherapy is effective and safe for neck metastatic carcinoma and the adverse reaction is mild.关键词
重组人p53腺病毒/颈部转移性癌/化疗/基因治疗Key words
Recombinant human adenovirus p53/Neck metastatic carcinoma/Chemotherapy/Gene therapy引用本文复制引用
常娜,吴韦炜,徐成胜,钱立庭..重组人p53腺病毒联合化疗治疗颈部转移癌的临床疗效观察[J].中国医学创新,2013,(17):3-4,2.
